Posts

Posted on

K92 Mining Announces Grant of Stock Options

VANCOUVER, British Columbia, May 03, 2021 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQX: KNTNF) announces the grant of 2,420,000 stock options to employees, directors and consultants of the Company, pursuant to the terms of the Company’s Stock Option Plan. The options are exercisable at $8.02 per share, expire five years from the date of grant, and vest in increments over twelve months from the date of grant.

About K92

K92 Mining Inc. is engaged in the production of gold, copper and silver from the Kora deposit at the Kainantu Gold Mine in the Eastern Highlands province of Papua New Guinea, as well as exploration and development of mineral deposits in the immediate vicinity of the mine. The Company declared commercial production from Kainantu in February 2018 and is in a strong financial position.

The Company commenced an expansion of the mine based on an updated Preliminary Economic Assessment on the property which was published in January 2019 and updated in July 2020. K92 is operated by a team of mining company professionals with extensive international mine-building and operational experience.

On Behalf of the Company,

John Lewins, Chief Executive Officer and Director

For further information, please contact David Medilek, P.Eng., CFA at +1-604-687-7130.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. All statements that address future plans, activities, events, or developments that the Company believes, expects or anticipates will or may occur are forward-looking information, including statements regarding the realization of the preliminary economic analysis for the Kainantu Mine, expectations of future cash flows, the planned plant expansion, production results, cost of sales, sales of production, potential expansion of resources and the generation of further drilling results which may or may not occur. Forward-looking statements and information contained herein are based on certain factors and assumptions regarding, among other things, the market price of the Company’s securities, metal prices, exchange rates, taxation, the estimation, timing and amount of future exploration and development, capital and operating costs, the availability of financing, the receipt of regulatory approvals, environmental risks, title disputes, failure of plant, equipment or processes to operate as anticipated, accidents, labour disputes, claims and limitations on insurance coverage and other risks of the mining industry, changes in national and local government regulation of mining operations in PNG, mitigation of the Covid-19 pandemic, continuation of the lifted state of emergency, and regulations and other matters. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 



Posted on

Ascendant Resources Announces the Appointment of Mr. Joao Barros as President

  • Seasoned Mining Veteran With Focused Expertise of Iberian Pyrite Belt to Take Lagoa Salgada Property Through Bankable Feasibility Study and Development

NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

TORONTO, May 03, 2021 (GLOBE NEWSWIRE) — Ascendant Resources Inc. (TSX: ASND) (“Ascendant” or the “Company”) is pleased to announce the appointment of Mr. Joao Barros to the position of President, Ascendant Resources, where he will continue to oversee the exploration and development efforts at the Lagoa Salgada VMS project (“Lagoa Salgada”), located on the prolific Iberian Pyrite Belt in Portugal. Mr. Barros is a Civil Engineer with an MSc in Geology with more than 17 years of experience tied to the mining industry in Portugal.

Mr. Barros is currently President of Ascendant Portugal and President of Redcorp – Empreendimentos Mineiros, Lda., the joint venture company in which Ascendant has its investment and is earning an 80% interest in Lagoa Salgada. Mr. Barros has been instrumental in the advancement of the Lagoa Salgada project under Ascendant’s direction. Mr. Barros has a strong technical background having significant senior mining management experience with the exploration and development of numerous polymetallic VMS, gold and tungsten operations in Portugal.

Ascendant is currently moving towards Feasibility and development at Lagoa Salgada and is anticipating three key milestones in the coming months:

  • End May: New 43-101 Mineral Resource Estimate following latest drilling program
  • End June: PFS Quality Metallurgical Testwork Report
  • End July: New 43-101 PEA to include North & South zones

Ascendant also announces the resignation of Chris Buncic as CEO of the company effective April 30, 2021. Mark Brennan, Executive Chairman will assume CEO responsibilities in the interim.

Alonso Sotomayor, currently Corporate Controller, will be named Interim CFO following the resignation of Rohan Hazelton effective April 30, 2021.

Mark Brennan, Executive Chairman commented, “We are thrilled to have Joao join us at Ascendant. Joao comes from an esteemed family steeped in the recent history of mining in Portugal. His depth of experience in mining project management, having built several operations in Portugal over the past two decades, will add tremendous strength to Ascendant’s management team. We are grateful for his guidance and contributions to our exploration success thus far at Lagoa Salgada, and we have the greatest confidence in our continued success under his direction in Portugal.”

He continued, “The Company would like to thank Chris for his efforts to transition the focus of Ascendant from its operation of the complex El Mochito mine to the very exciting prospect of developing the potentially world class Lagoa Salgada project. We would also like to thank Rohan for his discipline and versatility in keeping a stable ship while the very difficult market environment of lower zinc prices during 2020. We hope that the development of the Lagoa Salgada project will be a testimony of their efforts.”

Ascendant is also pleased to announce that it has retained Hybrid Financial Ltd. The service provided by Hybrid to the Company is a database of Registered Financial Professionals in North America. Hybrid is not promoting the specific purchase or sale of securities. It provides its database, technology, and call center services to enable the issuer to disseminate its information to Financial Professionals only. Hybrid provides its services directly to the Company.

Hybrid has agreed to comply with all applicable securities laws and the policies of the TSX Exchange (the “TSX”) in providing the Services.

Hybrid has been engaged by the Company for an initial period of 6 months starting November 23, 2020 (the “InitialTerm”) and then shall be renewed automatically for successive 3 month periods thereafter, unless terminated by the Company in accordance with the Agreement. Hybrid will be paid a monthly fee of $22,000 plus applicable taxes, during the Initial Term.

Hybrid Financial connects issuers to the investment community across North America. Using a data driven approach, Hybrid provides its clients with comprehensive coverage of both American and Canadian markets. Hybrid Financial has offices in Toronto and Montreal.

About Ascendant Resources Inc.

Ascendant is a Toronto-based mining company focused on the exploration and development of the highly prospective Lagoa Salgada VMS project located on the prolific Iberian Pyrite Belt in Portugal. Through focused exploration and aggressive development plans, the Company aims to unlock the inherent potential of the project, maximizing value creation for shareholders.

Lagoa Salgada contains over 12.8 million tonnes of M&I Resources and 10.3 million tonnes in Inferred Resources and demonstrates typical mineralization characteristics of Iberian Pyrite Belt VMS deposits containing zinc, copper, lead, tin, silver and gold. Extensive exploration upside potential lies both near deposit and at prospective step-out targets across the large 10,700ha property concession. The project also demonstrates compelling economics with scalability for future resource growth in the results of the Preliminary Economic Assessment. Located just 80km from Lisbon, Lagoa Salgada is easily accessible by road and surrounded by exceptional Infrastructure. Ascendant holds a 21.25% interest in the Lagoa Salgada project through its 25% position in Redcorp – Empreendimentos Mineiros, Lda, (“Redcorp”) and has an earn-in opportunity to increase its interest in the project to 80%. Mineral & Financial Investments Limited owns the additional 75% of Redcorp. The remaining 15% of the project is held by Empresa de Desenvolvimento Mineiro, S.A., a Portuguese Government owned company supporting the strategic development of the country’s mining sector. The Company’s interest in the Lagoa Salgada project offers a low-cost entry to a potentially significant exploration and development opportunity, already demonstrating its mineable scale.

The Company’s common shares are principally listed on the Toronto Stock Exchange under the symbol “ASND”. For more information on Ascendant, please visit our website at www.ascendantresources.com.

Additional information relating to the Company, including the Preliminary Economic Assessment referenced in this news release, is available on SEDAR at www.sedar.com.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

For further information please contact:

Nick Campbell
Manager, Corporate Development
Tel: 905 630 0148
[email protected]


Forward Looking Information


     
This news release contains “forward-looking statements” and “forward-looking information” (collectively, “forward-looking information”) within the meaning of applicable Canadian securities legislation. All information contained in this news release, other than statements of current and historical fact, is forward-looking information. Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “budget”, “guidance”, “scheduled”, “estimates”, “forecasts”, “strategy”, “target”, “intends”, “objective”, “goal”, “understands”, “anticipates” and “believes” (and variations of these or similar words) and statements that certain actions, events or results “may”, “could”, “would”, “should”, “might” “occur” or “be achieved” or “will be taken” (and variations of these or similar expressions). Forward-looking information is also identifiable in statements of currently occurring matters which may continue in the future, such as “providing the Company with”, “is currently”, “allows/allowing for”, “will advance” or “continues to” or other statements that may be stated in the present tense with future implications. All of the forward-looking information in this news release is qualified by this cautionary note.

Forward-looking information in this news release includes, but is not limited to, statements regarding the exploration activities and the results of such activities at the Lagoa Salgada Project, the ability of the Company to advance the Lagoa Salgada Project to a Preliminary Economic Assessment, and the ability of the Company to fund the exploration with funds from operations. Forward-looking information is based on, among other things, opinions, assumptions, estimates and analyses that, while considered reasonable by Ascendant at the date the forward-looking information is provided, inherently are subject to significant risks, uncertainties, contingencies and other factors that may cause actual results and events to be materially different from those expressed or implied by the forward-looking information. The material factors or assumptions that Ascendant identified and were applied by Ascendant in drawing conclusions or making forecasts or projections set out in the forward-looking information include, but are not limited to, the success of the exploration activities at Lagoa Salgada Project, the Company advancing the project to a Preliminary Economic Assessment, the ability of the Company to fund the exploration program at Lagoa Salgada with funds from operations , and
other events that may affect Ascendant’s ability to develop its project; and no significant and continuing adverse changes in general economic conditions or conditions in the financial markets. 



Posted on

Avivagen Announces Recurring Order for OxC-betaTM Livestock

Avivagen Announces Recurring Order for OxC-betaTM Livestock

  • Largest purchase amount and longest duration purchase to-date
  • Four tonne per month order secured
  • Order follows five successful OxC-betaTM Livestock commercial trials conducted with various species over the past six months

OTTAWA, Ontario–(BUSINESS WIRE)–
Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce that Meyenberg International Group, Avivagen’s consultant in Mexico, has entered into a contract which secures a four tonne per month recurring order forOxC-beta™ Livestock in Mexico.

The contract, which is 18 months from signing and includes an order for 500 Kgs delivered April 30th, is a commitment to purchase a minimum of four tonnes monthly, commencing in July, 2021 and ending October, 2022

“As we continue to see successful commercial trials conclude in those jurisdictions where OxC-beta™ Livestock is approved, we anticipate increased demand to follow, as has recently been demonstrated in Mexico and Thailand,” said Kym Anthony, Chief Executive Officer of Avivagen. “With numerous other commercial trials currently underway and nearing completion, it is our belief that the continued success of such company conducted trials will help to accelerate the adoption and use of OxC-beta™ Livestock in approved jurisdictions and beyond. It is our belief that OxC-beta™ Livestock, once started by a customer, becomes core to their continued operations and will drive recurring orders for years to come.”

Meyenberg International Group

With a client base across North America and a well-earned reputation for enabling rapid growth for clients expanding into LATAM, Meyenberg’s experience in Mexico has enabled Avivagen to quickly establish and grow sales in the country since securing regulatory approval in August 2019.

About OxC-beta™ Technology and OxC-beta™ Livestock

Avivagen’s OxC-beta™ technology is derived from Avivagen discoveries about β-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colours. Through support of immune function the technology provides a non-antibiotic means of promoting health and growth. OxC-beta™ Livestock is a proprietary product shown to be an effective and economic alternative to the antibiotics commonly added to livestock feeds. The product is currently available for sale in the United States, Philippines, Mexico, Taiwan, New Zealand, Thailand, Brazil, Australia and Malaysia.

Avivagen’s OxC-beta™ Livestock product is safe, effective and could fulfill the global mandate to remove all in-feed antibiotics as growth promoters. Numerous international livestock trials with poultry and swine using OxC-beta™ Livestock have proven that the product performs as well as, and, sometimes, in some aspects, better than in-feed antibiotics.

About Avivagen

Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that, by safely supporting immune function, promote general health and performance. It is a public corporation traded on the TSX Venture Exchange under the symbol VIV and is headquartered in Ottawa, Canada, based in partnership facilities of the National Research Council of Canada. For more information, visit www.avivagen.com. The contents of the website are expressly not incorporated by reference in this press release.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear”, “believe”, “consider”, “could”, “estimate”, “expect”, “if”, “intend”, “goal”, “hope”, “likely”, “may”, “plan”, “possibly”, “potentially”, “pursue”, “seem”, “should”, “whether”, “will”, “would” and similar expressions. Statements set out in this news release relating to the recurring nature of the orders under the contract described above, the anticipated date of fulfillment for the order described, Avivagen’s expectation that the customer in question will live up to its contractual commitment to purchase product monthly, anticipated increase in demand for Avivagen’s products, Avivagen’s expectation that commercial trials currently underway will be completed and yield positive results, the anticipated impact of the results of such trials on demand for product, expectations as to the recurring and long term nature of a customer’s purchases once they begin using Avivagen’s products and the possibility for OxC-beta™ Livestock to replace antibiotics in livestock feeds as well as fill a critical need for health support in certain livestock applications where antibiotics are precluded are all forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. For instance, the order described may not result in new orders for Avivagen’s products, the customer plans may change due to many reasons, timing of fulfillment of the order may be delayed beyond current expectation for a number of reasons which would push fulfillment and recognition of revenues for this order into a future quarter or cause such order to be cancelled, the parties to the contract described may not live up to their contractual commitments and/or may agree to amend such contract to reduce the commitments described above, demand for Avivagen’s products may not continue to grow and could decline, commercial trials may not be completed and, if completed, may not yield results that are positive or which lead to additional demand for Avivagen’s products, except as otherwise stated, customers are under no obligation to continue using Avivagen’s products and Avivagen’s products may not gain market acceptance or regulatory approval in new jurisdictions or for new applications, including human applications, and may not be widely accepted as a replacement for antibiotics in livestock feeds, , in each case due to many factors, many of which are outside of Avivagen’s control. Readers are referred to the risk factors associated with the business of Avivagen set out in Avivagen’s most recent management’s discussion and analysis of financial condition available at www.SEDAR.com. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Copyright © 2021 Avivagen Inc. OxC-beta™ is a trademark of Avivagen Inc

Avivagen Inc.

Drew Basek

Director of Investor Relations

100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6

Phone: 416-540-0733

E-mail: [email protected]

Kym Anthony

Chief Executive Officer

100 Sussex Drive, Ottawa, Ontario, Canada K1A 0R6

Head Office Phone: 613-949-8164

Website: www.avivagen.com

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Biotechnology Agriculture Health Natural Resources

MEDIA:

Posted on

HEXO Corp Announces Repayment of Credit Facility

OTTAWA, May 03, 2021 (GLOBE NEWSWIRE) — HEXO Corp (“HEXO”, or the “Company”) (TSX: HEXO; NYSE: HEXO) today announced that it has repaid, effective April 30, 2021, the total outstanding balance on its credit facility established under its credit agreement dated February 14, ‎‎2019 with Canadian Imperial Bank of Commerce as sole bookrunner, co-lead arranger and administrative agent, and Bank of Montreal as co-lead arranger and syndication agent, together with accrued interest and associated fees, in the ‎amount of approximately $28.9 million.

“We believe repayment of the credit facility provides HEXO with flexibility as we continue to execute on our US expansion plans and our goal to become a top two Canadian LP by adult-use recreational cannabis sales,” said HEXO CEO and co-founder Sebastien St-Louis. “We would like to thank our lenders for their support, which has contributed to HEXO’s success to date.”

About HEXO (TSX: HEXO; NYSE: HEXO)

HEXO Corp is an award-winning consumer packaged goods cannabis company that creates and distributes innovative products to serve the global cannabis market. The Company serves the Canadian adult-use markets under its HEXO, HEXO Plus, Up, Original Stash and Bake Sale brands and the medical market under HEXO medical cannabis. For more information, please visit hexocorp.com.

Forward Looking Statements

This press release contains forward-looking information and forward-looking statements within the meaning of applicable securities laws (“forward-looking statements”). Forward-looking statements are based on certain expectations and assumptions and are subject to known and unknown risks and uncertainties and other factors that could cause actual events, results, performance and achievements to differ materially from those anticipated in these forward-looking statements. Forward-looking statements should not be read as guarantees of future performance or results. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements as a result of new information or future events, or for any other reason.

Investor Relations:

[email protected]

www.hexocorp.com 

Media Relations:

(819) 317-0526

[email protected]



Posted on

Teleflex Announces Quarterly Dividend

WAYNE, Pa., May 03, 2021 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 15, 2021 to shareholders of record at the close of business on May 14, 2021.   Additional information about Teleflex can be obtained from the company’s website at www.teleflex.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular access, interventional cardiology and radiology, anesthesia, emergency medicine, surgical, urology and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rüsch®, UroLift®, and Weck® – trusted brands united by a common sense of purpose.

Source:

Teleflex Incorporated
Jake Elguicze
Treasurer and Vice President, Investor Relations
610-948-2836



Posted on

Palantir Announces Hiring of First USG Chief Medical Officer

Palantir Announces Hiring of First USG Chief Medical Officer

Continues Momentum in Healthcare and Life Sciences

DENVER–(BUSINESS WIRE)–
Palantir Technologies today announced the hiring of Dr William J. Kassler, MD, MPH, as its first US Government Chief Medical Officer, bringing years of clinical and public health expertise to Palantir as it continues its expansion in the private and public health sectors.

Dr. Kassler is joining Palantir from IBM Watson Health and worked throughout his career at the intersection of clinical care and population health. He will lead the Public Health and Life Sciences teams across Palantir’s USG and international business.

Over the past few years, Palantir has grown its healthcare business and in recent months made significant new senior hires with deep domain expertise in life sciences, pharmaceuticals, and public health. Dr. Kassler and the expanded team will continue to build on Palantir’s success in public and commercial healthcare around the globe, putting its technology to work to solve the world’s most important health problems.

“Palantir has played a key role in mitigating the global Covid-19 pandemic, supporting more than 100 organizations in their response to the pandemic, and helping the U.S. and the U.K with vaccine distribution,” said Shyam Sankar, Palantir’s COO. “Palantir software has also been used in drug discovery, biotechnology, scientific research, and to mitigate disparities in public health. Dr. Kassler will play a key role in ensuring our healthcare work continues to prosper.”

“Palantir’s ability to lead so many international public health initiatives from the start of this pandemic was truly impressive and serves as a model for the type of technology investments governments around the world need to make,” said Dr. Kassler. “I’m inspired by Palantir’s mission and team, and excited to get to work. To emerge from this pandemic stronger, society will need to make significant improvements to how we approach public health.”

Dr. Kassler was IBM Watson Health’s Deputy Chief Health Officer and Chief Medical Officer for Government Health & Human Services and led their population health efforts. Before joining the private sector, he was Chief Medical Officer for the New England Region of the Centers for Medicare and Medicaid Services (CMS), and the State Health Officer for the New Hampshire Department of Health and Human Services. Dr. Kassler started his career at the Centers for Disease Control and Prevention (CDC).

He received his MD from the University of Massachusetts Medical School, an MS in nutrition from Case Western Reserve University, and an MPH from the University of California, Berkeley. He completed a primary care internal medicine residency at Brown University and was a Robert Wood Johnson Clinical Scholar at the University of California, San Francisco.

About Palantir Technologies

Palantir Technologies is a software company that builds enterprise data platforms for use by organizations with complex and sensitive data environments. From building safer cars and planes, to discovering new drugs and combating terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data. Additional information is available at https://www.palantir.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding our healthcare business and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate contracts. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.

Lisa Gordon

[email protected]

KEYWORDS: United States North America Colorado

INDUSTRY KEYWORDS: Data Management Biotechnology Technology Health General Health Pharmaceutical Research Software Networks Internet Science

MEDIA:

Logo
Logo
Posted on

Affinia Therapeutics Closes $110 Million Series B Financing

  • Financing co-led by EcoR1 Capital and Farallon Capital Management
  • Proceeds to support continued development of proprietary platform for rationally designed adeno-associated virus vectors (AAV) and advance programs into the clinic

WALTHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) — Affinia Therapeutics, an innovative gene therapy company with a proprietary platform for rationally designed adeno-associated virus (AAV) vectors and gene therapies for rare and non-rare diseases, today announced it has closed an oversubscribed $110 million Series B financing with a premier syndicate of life science investors, co-led by EcoR1 Capital and Farallon Capital Management. Additional new investors participating in the round include Avidity Partners, Casdin Capital, GV (formerly Google Ventures), Octagon Capital, Perceptive Advisors, RA Capital Management, TCG Crossover, and Woodline Partners LP. Existing investors Atlas Venture, F-Prime Capital, Lonza, Mass General Brigham Ventures, and New Enterprise Associates (NEA) also participated in the round. Affinia Therapeutics will use the proceeds of the Series B financing to further develop its proprietary gene therapy platform, advance programs into the clinic, and for general corporate purposes.

“Since founding the company, we have had the interest of leading biotech investors as well as strategic partners who see the potential of our gene therapy discovery platform to engineer novel vectors that overcome the limitations of conventional serotypes,” said Rick Modi, chief executive officer of Affinia Therapeutics. “We are excited to partner with this syndicate of top investors to expand our platform to regulatory elements and work toward the next generation of one-time, potentially curative medicines for broader use.”

In 2020, Affinia Therapeutics announced a Series A financing and a multi-year research collaboration with Vertex Pharmaceuticals. Earlier this year, the Company announced it strengthened its leadership team with the appointment of Charles Albright, Ph.D., and Petra Kaufmann, M.D., who joined as chief scientific officer and chief medical officer from Editas Medicine and Novartis Gene Therapies, respectively. Last week, the Company announced the acceptance of abstracts for the upcoming virtual American Society of Gene & Cell Therapy annual meeting. The abstracts are focused on novel vectors with enhanced capabilities for central nervous system and muscle diseases, and improved manufacturing yields.

The Company is chaired by Sean P. Nolan, previous chief executive officer of AveXis. In connection with the Series B financing, Caroline Stout, partner at EcoR1 Capital, has been appointed to Affinia Therapeutics’ board of directors.

“Gene therapies with novel vectors and regulatory elements have the potential to benefit a broad range of both rare and non-rare diseases,” said Ms. Stout. “We are impressed with Affinia Therapeutics’ leadership team and scientific progress and are pleased to support the Company at this critical juncture as it brings forth novel gene therapies with the potential to impact a wide range of diseases, giving new hope to patients.”

Founded in 2019, Affinia Therapeutics’ science originates from work done by Luk Vandenberghe, Ph.D., associate professor at Massachusetts Eye and Ear and Harvard Medical School and a co-inventor of AAV9. The Company recently expanded its state-of-the-art discovery laboratories in Waltham, Mass., to add process science, analytical development, and manufacturing pilot plant capabilities as it advances its programs into the clinic.

About Affinia Therapeutics

Affinia Therapeutics’ purpose is to develop gene therapies that can have a transformative impact on people affected by devastating rare and non-rare diseases. The Company’s proprietary platform enables it to methodically engineer novel AAV vectors and regulatory elements to make gene therapies with potentially improved tissue tropism, cell specificity, safety, and yields. With its innovative science, the Company is working to broaden the reach of life-changing gene therapies to meaningful numbers of patients with an initial focus on central nervous system (CNS) and muscle diseases with significant unmet need. For more information, visit www.affiniatx.com.

Affinia Therapeutics Contacts

Investors:

[email protected]

Media:

[email protected]



Posted on

Tilly’s, Inc. to Report Fiscal 2021 First Quarter Operating Results on June 3, 2021

Tilly’s, Inc. to Report Fiscal 2021 First Quarter Operating Results on June 3, 2021

IRVINE, Calif.–(BUSINESS WIRE)–
Tilly’s, Inc. (NYSE: TLYS) today announced that the company will release its financial results for the first quarter of fiscal 2021 ended May 1, 2021, after the market close on Thursday, June 3, 2021. Edmond Thomas, President and Chief Executive Officer, and Michael Henry, Executive Vice President and Chief Financial Officer, will host a conference call that afternoon (June 3, 2021) at 4:30 p.m. ET (1:30 p.m. PT) to discuss the financial results.

Investors and analysts interested in participating in the call are invited to dial (877) 407-4018 (domestic) or (201) 689-8471 (international) at 4:25 p.m. ET (1:25 p.m. PT). The conference call will also be available to interested parties through a live webcast at www.tillys.com. Please visit the website and select the “Investor Relations” link at least 15 minutes prior to the start of the call to register and download any necessary software.

A telephone replay of the call will be available until June 17, 2021, by dialing (844) 512-2921 (domestic) or (412) 317-6671 (international) and entering the conference identification number: 13719420. Please note, participants must enter the conference identification number in order to access the replay.

About Tillys

Tillys is a leading specialty retailer of casual apparel, footwear and accessories for young men, young women, boys and girls with an extensive assortment of iconic global, emerging and proprietary brands rooted in an active and outdoor lifestyle. Tillys is headquartered in Irvine, California and, as of May 1, 2021, operated 238 total stores across 33 states, and its website, www.tillys.com.

Investor Relations:

Michael L. Henry

Executive Vice President, Chief Financial Officer

949-609-5599 x.17000

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Retail Specialty Department Stores Fashion

MEDIA:

Posted on

Community Redevelopment Engages Myron M. Jones and Millennium Acquisition Partners LLC to Serve as Head of Development

MIAMI, May 03, 2021 (GLOBE NEWSWIRE) — Crosswind Renewable Energy Corp. dba Community Redevelopment (OTC Pink: CWNR) (“the Company”), a community oriented real estate redeveloper targeting economic growth and opportunity zones in secondary and tertiary markets, announced today that it has engaged Myron M. Jones as Head of Development. Mr. Jones currently serves as the principal of Millennium Acquisition Partners LLC, a real estate services and investment company doing business in the Washington, DC, Baltimore, MD, and New York metro areas. As Head of Development for Community Redevelopment, Mr. Jones will provide the Company with guidance on initial feasibility, as well as pre-development and construction, in the form of advisory, planning, financial modeling, and presentation.

Charles Arnold, Chief Executive Officer of Community Redevelopment, said, “Myron Jones is a top-tier professional with an impressive background in the U.S. real estate and capital markets sector. His experience will play a major role in helping Community Redevelopment bring commerce and affordable housing to underserved areas.” Mr. Arnold continued, “Myron’s leadership and track record in feasibility and due diligence of early stage real estate projects will help accelerate some of the transactions we have on the table.”

As the principal of Millennium Acquisition Partners, LLC, Mr. Jones has focused primarily on mixed-use and transit oriented projects that are environmentally conscious and promote new urbanism. He has primarily been responsible for feasibility and due diligence of early stage real estate projects, the acquisition and disposition of distressed institutional assets, and providing underwriting support for institutional funding and equity partnerships. Millennium has negotiated and advised clients on more than $26 Million in debt and equity placement.

Prior to Millennium Acquisition Partners, LLC, Mr. Jones participated in the feasibility and predevelopment phases of more than $250 million in re-development. Mr. Jones assisted with a project currently under construction consisting of 550,000 square feet of mixed use development set on 25 acres, the creation of a TIF district, and the acquisition of $16.1 Million Tax Increment Financing. His skillset also includes writing a successful Minority Business Enterprise (MBE) plan, as well as underwriting support for institutional funding and equity partnerships.

Mr. Jones has managed several multi-family development projects totaling more than $105 million in market value and was responsible for project underwriting, and overseeing third party consultants. He evaluated construction, architect and engineering proposals and contracts, while managing completion of the entitlement process.

Myron Jones, Head of Development for Community Redevelopment said, “I am very impressed with Community Redevelopment’s plan to provide workforce, veterans and senior housing in low-income areas. Mixed use developments that provide a safe, comfortable environment, as well as increased commerce, have always been of tremendous interest to me.” Mr. Jones continued, “I look forward to helping contribute to the future growth and success of the company.”

Community Redevelopment recently filed its Form 10-K and Form 10-12G/A to become a fully reporting company with the U.S. Securities and Exchange Commission.

About Community Redevelopment

Community Redevelopment, Inc. operates as a community oriented real estate redeveloper targeting economic growth, housing for veterans, and opportunity zones in secondary and tertiary value-added markets. The Company is primarily focusing its efforts on bringing commerce and affordable housing to underserved areas. Community Redevelopment plans to provide numerous opportunities to improve low income neighborhoods for residential, commercial, and industrial opportunities through government incentives, long term partnerships and agreements. Our mission is to rebuild depressed communities, change the direction of youth and improve the quality of life in those communities, and provide our investors with an opportunity to profit. We intend to accomplish this by focusing on partnerships between the public and private sector to generate both business interest and business activity in low income neighborhoods that have gone unnoticed by the development community at large, while repairing and amending relationships in these underserved communities.

Community Redevelopment, Inc. is not an opportunity zone fund, or a real estate investment trust. Community Redevelopment, Inc. is a real estate developer offering potential investors an opportunity to participate in the process of investing in real estate projects that could improve the quality of life for residents of low income neighborhoods, via a publicly traded company. The Company intends to work with other real estate developers, as well as local and state government agencies to complete its projects in these communities.

Forward-Looking Statements

This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company’s current expectations regarding future events, including its ability to raise sufficient capital, as well as the Company’s plans for real estate development, the Company’s regulatory environment, and the Company’s overall business strategy. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the funding necessary for the Company’s future development plans, local zoning laws, access to capital, changes to government regulation, unexpected adverse events or safety issues, the timing and ability of the Company to raise additional funding as needed for continued operations, and the impact of the COVID-19 pandemic on general economic, regulatory and political conditions. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see the Company’s filings with OTC Markets on OTCMarkets.com. The Company undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
For Investor Relations, please contact:

David Kugelman
(866) 692-6847 Toll Free – U.S. & Canada
(404) 281-8556 Mobile and WhatsApp
Skype: kugsusa
[email protected]

 



Posted on

The Estée Lauder Companies Inc. Declares Quarterly Dividend of $.53 Per Share

The Estée Lauder Companies Inc. Declares Quarterly Dividend of $.53 Per Share

NEW YORK–(BUSINESS WIRE)–The Estée Lauder Companies Inc. (NYSE: EL) will pay a quarterly dividend of $.53 per share on the Company’s Class A Common Stock and Class B Common Stock on June 15, 2021 to stockholders of record at the close of business on May 28, 2021.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The Company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, Tommy Hilfiger, M·A·C, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford Beauty, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, Kilian Paris, BECCA, Too Faced and Dr. Jart+.

ELC-F

Investors: Rainey Mancini

(212) 284-3049

Media: Jill Marvin

(212) 572-4438

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Fashion Luxury Cosmetics Retail Specialty

MEDIA:

Logo
Logo